Statement 28 October 2021

Joint Industry Statement by ABPI, EFPIA, Farmindustria, IMC, IFPMA, JPMA, LEEM, PhRMA, and vfa on the UN Climate Change Conference (COP26): Biopharmaceutical Industry Actions to Tackle Climate Change


Global public health is inextricably linked to the health of the planet. Climate change, air pollution and other environmental challenges have a demonstrable impact on public health around the world.

As part of the global health care system, the innovative biopharmaceutical industry is committed to minimizing our impact on the planet as well as to researching and developing new health products that manage and mitigate health risks from environmental challenges.

Global industry has led the way in tackling COVID-19 and we are fully committed to partnering with governments and health systems across the world to take concerted action to address climate change. We are investing in research and development in greener products, as well as more sustainable production and distribution practices, that enable us to deliver medical innovation to patients in ways that protect and support the environment.

Our companies are already working on initiatives to reduce carbon emissions across our own operations and value chains, invest in renewable electricity and energy efficiency measures, recycle and cut water use and on bespoke projects which will impact positively on the environment.

Our member companies have taken significant actions to address climate change.  Eighty percent of the largest innovative companies have set net-zero or carbon-neutrality targets and many more have committed to ambitious short-term greenhouse gas emissions reduction efforts. Our companies’ efforts are already yielding results in terms of emissions reductions, energy efficiency savings, and increased shares of renewable electricity.  Investment in science and research, alongside co-ordinated global cooperation, will deliver solutions to the biggest challenges of our age including the climate crisis.


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster